These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 8927669)

  • 21. An open-label trial of venlafaxine in body dysmorphic disorder.
    Allen A; Hadley SJ; Kaplan A; Simeon D; Friedberg J; Priday L; Baker BR; Greenberg JL; Hollander E
    CNS Spectr; 2008 Feb; 13(2):138-44. PubMed ID: 18227745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.
    Bystritsky A; Ackerman DL; Rosen RM; Vapnik T; Gorbis E; Maidment KM; Saxena S
    J Clin Psychiatry; 2004 Apr; 65(4):565-8. PubMed ID: 15119922
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Medication augmentation after the failure of SSRIs for depression.
    Trivedi MH; Fava M; Wisniewski SR; Thase ME; Quitkin F; Warden D; Ritz L; Nierenberg AA; Lebowitz BD; Biggs MM; Luther JF; Shores-Wilson K; Rush AJ;
    N Engl J Med; 2006 Mar; 354(12):1243-52. PubMed ID: 16554526
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorder.
    Schneier FR; Feusner J; Wheaton MG; Gomez GJ; Cornejo G; Naraindas AM; Hellerstein DJ
    J Psychiatr Res; 2023 May; 161():364-370. PubMed ID: 37004409
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Buspirone: future directions.
    Apter JT; Allen LA
    J Clin Psychopharmacol; 1999 Feb; 19(1):86-93. PubMed ID: 9934947
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacotherapy and psychotherapy for body dysmorphic disorder.
    Ipser JC; Sander C; Stein DJ
    Cochrane Database Syst Rev; 2009 Jan; 2009(1):CD005332. PubMed ID: 19160252
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aripiprazole as an augmentation agent in treatment-resistant body dysmorphic disorder.
    Uzun O; Ozdemir B
    Clin Drug Investig; 2010; 30(10):707-10. PubMed ID: 20701402
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inositol augmentation of serotonin reuptake inhibitors in treatment-refractory obsessive-compulsive disorder: an open trial.
    Seedat S; Stein DJ
    Int Clin Psychopharmacol; 1999 Nov; 14(6):353-6. PubMed ID: 10565802
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Premenstrual syndrome: a single-blind study of treatment with buspirone versus fluoxetine.
    Nazari H; Yari F; Jariani M; Marzban A; Birgandy M
    Arch Gynecol Obstet; 2013 Mar; 287(3):469-72. PubMed ID: 23073723
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The addition of buspirone to SSRI in the treatment of adolescent obsessive-compulsive disorder. A study of six cases.
    Thomsen PH; Mikkelsen HU
    Eur Child Adolesc Psychiatry; 1999 Jun; 8(2):143-8. PubMed ID: 10435463
    [No Abstract]   [Full Text] [Related]  

  • 31. Update on pharmacologic management of OCD: agents and augmentation.
    McDougle CJ
    J Clin Psychiatry; 1997; 58 Suppl 12():11-7. PubMed ID: 9393391
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder.
    Carpenter LL; McDougle CJ; Epperson CN; Price LH
    Drug Saf; 1996 Aug; 15(2):116-34. PubMed ID: 8884163
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Neurobiology and pharmacotherapy of social phobia].
    Aouizerate B; Martin-Guehl C; Tignol J
    Encephale; 2004; 30(4):301-13. PubMed ID: 15538306
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762].
    Carey PD; Vythilingum B; Seedat S; Muller JE; van Ameringen M; Stein DJ
    BMC Psychiatry; 2005 Jan; 5():5. PubMed ID: 15667657
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study.
    Li X; May RS; Tolbert LC; Jackson WT; Flournoy JM; Baxter LR
    J Clin Psychiatry; 2005 Jun; 66(6):736-43. PubMed ID: 15960567
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Possible serotonin syndrome associated with buspirone added to fluoxetine.
    Manos GH
    Ann Pharmacother; 2000; 34(7-8):871-4. PubMed ID: 10928399
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anxiolytic antidepressant augmentation.
    Sussman N
    J Clin Psychiatry; 1998; 59 Suppl 5():42-8; discussion 49-50. PubMed ID: 9635547
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does the presence of accompanying symptom clusters differentiate the comparative effectiveness of second-line medication strategies for treating depression?
    Gaynes BN; Farley JF; Dusetzina SB; Ellis AR; Hansen RA; Miller WC; Stürmer T
    Depress Anxiety; 2011 Nov; 28(11):989-98. PubMed ID: 21898717
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Skin picking as a symptom of body dysmorphic disorder.
    Phillips KA; Taub SL
    Psychopharmacol Bull; 1995; 31(2):279-88. PubMed ID: 7491380
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biological approaches to treatment-resistant obsessive compulsive disorder.
    Goodman WK; McDougle CJ; Barr LC; Aronson SC; Price LH
    J Clin Psychiatry; 1993 Jun; 54 Suppl():16-26. PubMed ID: 8331098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.